tiprankstipranks
Trending News
More News >
Percheron Therapeutics (AU:PER)
ASX:PER
Advertisement

Percheron Therapeutics (PER) Price & Analysis

Compare
13 Followers

PER Stock Chart & Stats


Percheron Therapeutics News

PER FAQ

What was Percheron Therapeutics’s price range in the past 12 months?
Percheron Therapeutics lowest share price was <AU$0.01 and its highest was AU$0.14 in the past 12 months.
    What is Percheron Therapeutics’s market cap?
    Percheron Therapeutics’s market cap is $11.42M.
      When is Percheron Therapeutics’s upcoming earnings report date?
      Percheron Therapeutics’s upcoming earnings report date is Aug 28, 2025 which is yesterday.
        How were Percheron Therapeutics’s earnings last quarter?
        Currently, no data Available
        Is Percheron Therapeutics overvalued?
        According to Wall Street analysts Percheron Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does Percheron Therapeutics pay dividends?
          Percheron Therapeutics does not currently pay dividends.
          What is Percheron Therapeutics’s EPS estimate?
          Percheron Therapeutics’s EPS estimate for its next earnings report is not yet available.
          How many shares outstanding does Percheron Therapeutics have?
          Percheron Therapeutics has 1,087,437,600 shares outstanding.
            What happened to Percheron Therapeutics’s price movement after its last earnings report?
            Currently, no data Available
            Which hedge fund is a major shareholder of Percheron Therapeutics?
            Currently, no hedge funds are holding shares in AU:PER

            Company Description

            Percheron Therapeutics

            Percheron Therapeutics Limited engages in the research and development of novel antisense pharmaceuticals in Australia. The company's product pipeline comprises ATL1102, an antisense inhibitor of CD49d, which is in Phase IIa clinical trial for the treatment of Duchenne Muscular Dystrophy, Limb Girdle Muscular Dystrophy R2, multiple sclerosis, asthma, and other inflammatory indications. Its product pipeline also includes Atesidorsen (ATL1103), an oligonucleotide targeting growth hormone receptor designed to block growth hormone receptor expression thereby reducing levels of the hormone insulin-like growth factor-I in the blood, as well as to treat diseases associated with excessive growth hormone action that has completed Phase II clinical trial. The company was formerly known as Antisense Therapeutics Limited and changed its name to Percheron Therapeutics Limited in December 2023. Percheron Therapeutics Limited was incorporated in 2000 and is headquartered in Melbourne, Australia.

            Percheron Therapeutics (PER) Earnings & Revenues

            Similar Stocks
            Company
            Price & Change
            Follow
            Cann Group
            Ecofibre
            Epsilon Healthcare Limited
            Invion
            Hygrovest Limited

            Ownership Overview

            10.20%89.80%
            10.20% Insiders
            Mutual Funds
            ― Other Institutional Investors
            89.80% Public Companies and
            Individual Investors

            Options Prices

            Currently, No data available
            ---
            Popular Stocks
            What am I Missing?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis